Novel Strategies for Allergy Immunotherapy

被引：0
作者：
Reisacher W.R. [1 ]
Wang A. [1 ]
机构：
[1] Presbyterian Hospital/Weill Cornell Medical College, 1305 York Avenue, 5th Floor, New York, 10021, NY
来源：
Current Otorhinolaryngology Reports | 2013年 / 1卷 / 2期
关键词：
Allergy; Antigen-presenting cells; Antigens; Asthma; Delivery; Epitopes; Immunotherapy; Oral mucosa; Peptide; Recombinant; Rhinoconjunctivitis; Subcutaneous; Sublingual;
D O I：
10.1007/s40136-013-0009-6
中图分类号：
学科分类号：
摘要：
This article reviews the literature on allergen modifications and novel routes of delivery for antigen-specific immunotherapy for allergic disease. Allergen modifications include the use of recombinant proteins, combining antigens with infectious carrier proteins, peptide immunotherapy, and genetic vaccines containing the code for allergenic proteins. Novel routes of delivery include oral immunotherapy, intralymphatic immunotherapy, epicutaneous immunotherapy, and oral mucosal immunotherapy. Allergen depot preparations, such as biodegradable, injectable microspheres and sublingual tablets, have also been developed. Current research in immunotherapy for allergic disease has focused on improving efficacy and patient adherence to therapy, while minimizing the risks of serious adverse events. © 2013, Springer Science+Business Media New York.
引用
收藏
页码：119 / 126
页数：7
相关论文
共 89 条
[71]  
Nickoloff B.J., Naidu Y., Perturbation of epidermal barrier function correlates with initiation of cytokine cascade in human skin, J Am Acad Dermatol., 30, pp. 535-546, (1994)
[72]  
Senti G., von Moos S., Tay F., Epicutaneous allergen-specific immunotherapy ameliorates grass pollen-induced rhinoconjunctivitis: a double-blind, placebo-controlled dose escalation study, J Allergy Clin Immunol., 129, pp. 128-135, (2012)
[73]  
Mondoulet L., Dioszeghy V., Ligouis M., Epicutaneous immunotherapy on intact skin using a new delivery system in a murine model of allergy, Clin Exp Allergy., 40, pp. 659-667, (2010)
[74]  
Dupont C., Kalach N., Soulaines P., Cow’s milk epicutaneous immunotherapy in children: a pilot trial of safety, acceptability, and impact on allergic reactivity, J Allergy Clin Immunol., 125, pp. 1165-1167, (2010)
[75]  
Epicutaneous immunotherapy in peanut allergy in children (ARACHILD)
[76]  
Dahl R., Andersen P., Chivato T., Et al., National prevalence of respiratory allergic disorders, Respir Med., 98, pp. 398-403, (2004)
[77]  
Malling H.J., Lund L., Ipsen H., Et al., Safety and immunological changes during specific sublingual immunotherapy with SQ standardized grass allergen tablets, J Investig Allergol Clin Immunol., 16, pp. 162-168, (2006)
[78]  
Durham S.R., Yang W.H., Pedersen M.R., Et al., Sublingual once-daily grass-pollen immunotherapy: a randomized controlled trial in seasonal allergic rhinoconjunctivitis, J Allergy Clin Immunol., 117, pp. 802-809, (2006)
[79]  
Dahl R., Knapp A., Colombo G., Et al., Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis, J Allergy Clin Immunol., 118, pp. 434-440, (2006)
[80]  
Durham S.R., Emminger W., Kapp A., Et al., Long-term clinical efficacy in grass pollen-induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet, J Allergy Clin Immunol, 125, pp. 131-138, (2010)
123456789